No Data
No Data
Intensity Therapeutics Expands Board, Welcomes New Audit Director
Express News | Intensity Therapeutics Inc - in Connection With Dubin's Appointment, Size of Board Was Increased From Four Directors to Five
Express News | Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
Express News | Intensity Therapeutics-Pursuant to Collaboration Deal, Co to Supply Sakk With Int230-6 as Well as Funding in Amount of up to About $3.0 Mln
Express News | Intensity Therapeutics Signs Collaboration Agreement With The Swiss Group For Clinical Cancer Research SAKK To Conduct Phase 2 Breast Cancer Trial In Europe For INT230-6
Express News | Intensity Therapeutics, Inc. and the Swiss Group for Clinical Cancer Research Sakk Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for Int230-6, Intensity's Lead Drug Candidate
No Data